Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.2252W HIGH $5.70
Volume
1.71 M
Value Traded
9.87 M
Short % Float
20.73%
Days to Cover
9.0
+1.3%Week
-20.48%1 Month
-28.96%3 Month
-28.53%6 Month
-84.67%5 Year
-91.23%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
697.51 M
EPS (TTM)
-0.71
P/E Ratio
-
Ent. Value
537.02 M
Total Shares
299.36 M
Float Shares
186.78 M
Insiders
37.61%
Institutions
50.96%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SANA Catalyst Timeline
Dated clinical, regulatory and corporate events for Sana Biotechnology, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sana Biotechnology, Inc.
357Total events
7Upcoming
45Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Topline ReadoutSG293Clinical Data
SG293 initial clinical data generation
non-Hodgkin lymphomasource ↗
▲Full ResultsUP421Clinical Data
NEJM publication of 14-month follow-up data for UP421
type 1 diabetessource ↗
◆Oral PresentationPresentation
Presentation at Goldman Sachs 47th Annual Global Healthcare Conference
◆Oral PresentationSG293Presentation
Oral presentation of preclinical data for SG293 at ASGCT 2026
B-cell cancers and B-cell mediated autoimmune diseasessource ↗
▲Partnership / LicenseCorporate
Strategic collaboration with Mayo Clinic to advance SC451
type 1 diabetessource ↗
▲Full ResultsUP421Clinical Data
Positive 14-month results from UP421 IST showing survival and function without immunosuppression
type 1 diabetessource ↗
▲Partnership / LicenseCorporate
Strategic collaboration with Mayo Clinic to advance SC451
type 1 diabetessource ↗
▲Oral PresentationPresentation
14-month follow-up data presented at ATTD Conference
Type 1 Diabetessource ↗
▲Full ResultsUP421Clinical Data
Shared 12-month clinical results of UP421 type 1 diabetes study
type 1 diabetessource ↗
▲PublicationUP421Presentation
New England Journal of Medicine published positive 12-week clinical results of UP421
type 1 diabetessource ↗
◆Management ChangeCorporate
Appointment of Brian Piper as Executive Vice President, Chief Financial Officer
▲Full ResultsUP421Clinical Data
UP421 one-year follow-up data: cell survival and function
type 1 diabetessource ↗
▲Primary Endpoint MetUP421Clinical Data
UP421 met all primary and secondary endpoints
type 1 diabetessource ↗
▲PublicationPresentation
Nature Biotechnology publication of in vivo gene editing of human hematopoietic stem cells using fusogen platform
▲PublicationUP421Presentation
NEJM published positive 12-week clinical results of UP421 in type 1 diabetes
type 1 diabetessource ↗
▼Program DiscontinuationSC291DiscontinuedCorporate
Suspended development of allogeneic CAR T program SC291
B-cell mediated autoimmune diseasessource ↗
▼Program DiscontinuationSC262DiscontinuedCorporate
Suspended development of allogeneic CAR T program SC262
oncologysource ↗
▲Preclinical PoCSG293Preclinical
SG293 demonstrates deep B-cell depletion and immune reset in non-human primates
B-cell cancers and/or B-cell mediated autoimmune diseasessource ↗
◆Oral PresentationPresentation
Presentation at Morgan Stanley 23rd Annual Global Healthcare Conference
▼Equity OfferingCorporate
Closed sale of 3,358,208 shares at $3.35 per share, full exercise of underwriters' option, gross proceeds ~$86.3M
▲PublicationUP421Presentation
12-week results published in New England Journal of Medicine
type 1 diabetessource ↗
▼Equity OfferingCorporate
Pricing of underwritten public offering of 20,895,522 shares and pre-funded warrants
▲PublicationUP421Presentation
NEJM publication of 12-week results from UP421 study
type 1 diabetessource ↗
▲Oral PresentationUP421Presentation
Six-month results presented at World Transplant Congress 2025
type 1 diabetessource ↗
▲Oral PresentationUP421Presentation
Six-month follow-up results presented at ADA 2025
type 1 diabetessource ↗
◆Oral PresentationPresentation
Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
▲Full ResultsUP421Clinical Data
Positive 6-month clinical results presented at ADA and World Transplant Congress 2025
type 1 diabetessource ↗
▲Full ResultsUP421Clinical Data
12-week clinical data for UP421 showing immune evasion and C-peptide production
type 1 diabetessource ↗
Past FDA Catalysts and PDUFA Decisions
How SANA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | SC262 (HIP-modified CD22-directed allogeneic CAR T) | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 60%
Micro Cap(rank 395 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SC291 Monoclonal antibodyNCT06294236 | Lupus Erythematosus | Phase 1 | ACTIVE NOT_RECRUITING | 7 | Mar 1, 2028 | ||||||
| SC262 Small moleculeNCT06285422 | Non Hodgkin's Lymphoma | Phase 1 | ACTIVE NOT_RECRUITING | 6 | Mar 1, 2029 | ||||||
| SC291 Small moleculeNCT05878184 | Non Hodgkin Lymphoma | Phase 1 | ACTIVE NOT_RECRUITING | 16 | Nov 4, 2038 |
Clinical Trial Results
Readouts, endpoints and source filings for every SANA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SC451 | Type 1 Diabetes | Phase 1/2 | 2026-07-13 | C-peptide levels at month 14 are comparable to those observedRead More | Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 DiabetesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| PATEL DHAVALKUMAR DHIRAJLALOfficer (EVP, Chief Scientific Officer) | Option | 125,000 224,510 held | $0.00 | 08/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SANA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.6 % | 65.44 M | 18.75 M |
SANA Institutional Ownership Trends
SANA Short Interest
Shares sold short, counted twice a month.
20.73%
Short % of Float
of tradable shares sold short
38.7M
Shares Sold Short
-6.4% vs prior count
9.0 High
Days to Cover
trading days of normal volume to buy every short share back
4.3M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SANA ranks across every disease it competes in
Competitive Position is a premium feature
See how SANA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSANA News
SANASana Biotechnology to Present at September 2026 Investor Conferences
Sana Biotechnology, Inc. will present at four investor conferences in September 2026, providing a business overview and updates. The conferences include the Wells Fargo Healthcare Conference, Citi's Biopharma Back-to-School Conference, the Morgan Stanley Global Healthcare Conference, and the HC Wainwright Global Investment Conference. Webcasts of the presentations will be available on Sana's website.
Read more →SANASana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates
Sana Biotechnology has reported positive developments in its ongoing projects. The company is making strides toward initiating the SC451 Phase 1/2 trial, with GLP toxicology studies and process transfer to a contract manufacturer in progress. Additionally, they are advancing clinical studies for SG293 in non-Hodgkin lymphoma and expect to generate initial clinical data soon.
Read more →SANA▼ -5.5%on this news· ran to -18% by day 3
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
Sana Biotechnology announced a follow-up publication in NEJM detailing long-term data on hypoimmune-modified islet cell transplantation for type 1 diabetes. The study indicates that these modified cells can function long-term without immunosuppression, achieving significant insulin production. Sana plans to file an IND application and initiate a Phase 1/2 trial for SC451, aiming for a one-time treatment solution.
Read more →SANASana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
Sana Biotechnology announced a symposium presentation at the EASD Annual Meeting 2026, showcasing clinical data from a first-in-human study of UP421, an allogeneic islet cell therapy for type 1 diabetes. This therapy utilizes Sana's hypoimmune platform technology and aims to eliminate the need for immunosuppression in patients. The meeting will take place in Milan, Italy from September 28 to October 2, 2026.
Read more →SANASana Biotechnology to Present at June 2026 Investor Conferences
Sana Biotechnology, Inc. announced its participation in two investor conferences in June 2026, where it will present a business overview and updates. The presentations will take place at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Webcasts of the presentations will be available on the company's website.
Read more →SANASana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
Sana Biotechnology, Inc. has successfully sold approximately 21.6 million shares of its common stock through its at-the-market facility for net proceeds totaling around $69 million. This capital raise, which includes contributions from RA Capital Management and an earlier $25 million investment from the Mayo Clinic, increases the total funds raised by the company to roughly $94 million since the end of Q1 2026. The additional capital is expected to extend Sana's operational cash runway to mid-2027, supporting its focus on developing engineered cell therapies.
Read more →SANASana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
Sana Biotechnology presented promising preclinical data for its SG293 CAR T cell therapy at the ASGCT 2026 Annual Meeting. The therapy demonstrated effective cell-specific delivery and significant B cell depletion in non-human primates without the need for lymphodepleting chemotherapy. This innovative approach aims to provide targeted treatment options for blood cancers and autoimmune disorders, with clinical trials expected to commence soon.
Read more →SANASana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
Sana Biotechnology reported its first quarter 2026 financial results, highlighting a strategic collaboration with Mayo Clinic aimed at enhancing treatment for type 1 diabetes. The company is progressing towards initiating Phase 1 trials for its gene-modified product SC451 and its CAR T-cell candidate SG293 within the year. Positive clinical results were shared concerning the UP421 therapy, showcasing its effectiveness without immunosuppression. Sana's financial profile shows a cash position of $101.1 million, allowing for continued operational support into 2027.
Read more →SANASana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
Sana Biotechnology, Inc. will present at the BofA Securities 2026 Healthcare Conference on May 12, 2026. CEO Steve Harr will provide a business overview during the webcast, which will be accessible on the company's Investor Relations page. A replay will be available for 30 days post-conference.
Read more →SANASana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
Sana Biotechnology has announced that its abstract featuring preclinical data from the SG293 CAR T product candidate will be presented at the ASGCT 2026 Annual Meeting. This innovative therapy utilizes a proprietary delivery technology aimed at targeting CD8+ T cells for B-cell cancers and autoimmune diseases. The company emphasizes the potential benefits of this approach while acknowledging the risks associated with drug development.
Read more →SANA▲ +8.4%on this news
Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451
Sana Biotechnology and Mayo Clinic have announced a strategic collaboration to advance SC451, an investigational therapy for type 1 diabetes. This partnership aims to enhance the development and accessibility of potentially curative treatments. Mayo Clinic will invest in Sana and leverage its expertise to improve clinical protocols and patient care for SC451, which is designed to provide long-term glucose control without ongoing insulin therapy.
Read more →SANA▲ +8.7%on this news
Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Sana Biotechnology reported positive 14-month results from a first-in-human study of islet cell transplantation for Type 1 diabetes, utilizing hypoimmune-modified cells without immunosuppression. The study showed sustained insulin production and improved glycemic control, with no safety issues reported. The company plans to file an IND application for its SC451 therapy and initiate a Phase 1 trial soon.
Read more →SANASana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Sana Biotechnology reported positive clinical results for its UP421 type 1 diabetes study, demonstrating safety and efficacy without immunosuppression. The company is advancing its SC451 therapy and expects to file an IND application soon. Additionally, they anticipate generating first-in-human data for their SG293 CAR T candidate. Financially, Sana raised $133.7 million, ensuring a cash runway into late 2026.
Read more →SANASana Biotechnology to Present at March 2026 Investor Conferences
Sana Biotechnology, Inc. has announced its participation in two investor conferences in March 2026. The company will webcast its presentations, which will include a business overview and updates on its engineered cell therapies. Replays of the presentations will be available for 30 days on their website.
Read more →SANASana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer
Sana Biotechnology has appointed Brian Piper as Executive Vice President and Chief Financial Officer. Piper brings extensive experience from various roles in the biopharmaceutical industry, including his previous positions at Scorpion Therapeutics and Prelude Therapeutics. His leadership is expected to be pivotal as the company advances its clinical programs for type 1 diabetes and B-cell related diseases.
Read more →SANAThis presentation contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securit
Sana Biotechnology, Inc. presented forward-looking statements about its strategic goals and advancements in developing therapies for Type 1 diabetes (T1D). The company is positioning itself to file an Investigational New Drug application for SC451 and commence Phase 1 trials in 2026, showcasing progress in immune evasion techniques. Despite the advancements, challenges remain, including the uncertainties surrounding drug development and the requirement for chronic immunosuppression in existing therapies.
Read more →SANA▲ +8.5%on this news
Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sana Biotechnology, Inc. announced that it will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will feature insights from CEO Steve Harr and provide a business overview. The webcast will be available on the company’s Investor Relations page, along with a 30-day replay option. This event highlights Sana's focus on engineered cell therapies.
Read more →SANA▼ -9.7%on this news
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform
Sana Biotechnology announced a publication in Nature Biotechnology detailing the successful in vivo gene editing of human hematopoietic stem cells (HSCs) using its Fusogen technology in preclinical models. This advancement showcases the technology's potential to treat diseases such as sickle cell disease and beta thalassemia without the need for conditioning chemotherapy. The publication underscores the ability of Fusogen to deliver various gene-editing tools effectively and safely.
Read more →SANASana Biotechnology to Present at December 2025 Investor Conferences
Sana Biotechnology, Inc. will present at two investor conferences in December 2025, featuring a business overview from CEO Steve Harr. The presentations will be accessible via webcast on the company's Investor Relations page, with replays available for 30 days. This engagement highlights Sana's commitment to transparency and investor relations.
Read more →SANASana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates
Sana Biotechnology raised $115.8 million in the third quarter of 2025, bringing its cash position to $153.1 million. The company suspended development of two allogeneic CAR T programs to focus on type 1 diabetes and in vivo CAR T initiatives. It expects to file an IND for SC451 as early as 2026 and for SG293 as early as 2027.
Read more →About Sana Biotechnology, Inc.
Headquarters188 EAST BLAINE STREET, SUITE 350, SEATTLE, WA
BIOPHARMAWATCH ELITE PLUS
Trade the next SANA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime